This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co (NYSE:LLY) and maintained a price target of $885.
康泰纳菲（Cantor Fitzgerald）分析师Louise Chen重申对礼来（Eli Lilly And Co）的股票给予超配（Overweight）评级，并维持885美元的目标股价。
The company is slated to report its second-quarter FY24 earnings on August 8.
公司计划于2024财年第二季度财报发布日8月8日公布其财报。
The analyst highlighted that Eli Lilly's GAAP and non-GAAP financial results for 2Q24 will include acquired IPR&D charges of ~$154 million on a pre-tax basis, representing a charge of ~$0.14 to both GAAP and non-GAAP earnings per share.
该分析师指出，礼来的2024财年第二季度财务报告（GAAP和非GAAP）将包括预税收购IPR&D的费用约合154百万美元，这代表GAAP和非GAAP每股收益分别为0.14美元的费用。
The following are some of the points the analyst lists that are important for the company's growth in the coming days.
以下是分析师列出的一些对公司未来增长至关重要的点。
The analyst expects U.S. approval for Lebrikizumab to treat atopic dermatitis in 2H24E.
该分析师预计，礼来的治疗特应性皮炎药物lebrikizumab将在2024年下半年获得美国批准。
Also Read: Eli Lilly Announces CFO Change
另外阅读：礼来宣布财务长变动
The analyst also expects Morphic acquisition to close in 3Q24. Morphic's lead program is a selective oral small molecule inhibitor of α4β7 integrin for the treatment of IBD.
该分析师还预计，Morphic收购将在2024年第三季度完成。Morphic的主要项目是抑制α4β7整合素的选择性口服小分子抑制剂，用于治疗炎症性肠病。
By the end of 2024, LLY expects to have results of SURMOUNT-5 which is its H2H study of tirzepatide vs. high-dose semaglutide in participants with obesity, said the analyst.
分析师称，到2024年底，礼来预计将获得SURMOUNt-5的研究结果，即tirzepatide与高剂量semaglutide在肥胖症患者中的H2H（头对头）研究。
The analyst sees the first set of Phase 3 results on orforglipron in T2D/obesity in 2025, from Phase 3 ACHIEVE T2D program.
该分析师预计，从ACHIEVE T2D项目的第3阶段“orforglipron”中，第一组T2D/肥胖症的结果将在2025年公布。
LLY submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the U.S. FDA with regulatory action anticipated as early as the end of this year, said the analyst.
分析师称，礼来已向美国食品和药物管理局提交了tirzepatide治疗中度至重度睡眠呼吸暂停和肥胖症的申请，并预计最早在今年年底获得监管动作的批准。
Key competitive readouts that the analyst looks forward to include, Novo Nordisk A/S's (NYSE:NVO) semaglutide in MASH, Akero Therapeutics Inc's (NASDAQ:AKRO) efruxifermin (FGF21 analog) in MASH and Novo Nordisk's CagriSema Phase 3 program for obesity.
分析师期待的主要竞争读数包括Novo Nordisk A/S（纳斯达克股票代码：NVO）的MASH，Akero Therapeutics Inc（NASDAQ股票代码：AKRO）的efruxifermin（FGF21类似物）在MASH中，以及Novo Nordisk的CagriSema第3期肥胖症方案。
Read Next:
阅读下文:
- Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
- 艾礼制药的32亿美元Morphic交易是“至关重要的”，尽管投资者关注肥胖症，仍具有“战略价值”，分析师表示。
Price Action: LLY shares are trading higher by 0.475 at $952.82 at last check Monday.
股价表现：在上周一的最后时刻，LLY股票以952.82美元的价格交易的0.475美元的高点。
Photo by rafapress on Shutterstock
rafaress的shutterstock照片